Natasha B. Leighl
Impact in
- Oncology top 0.1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 259
- Lung Cancer Diagnosis and Treatment 83
- Gastric Cancer Management and Outcomes 20
- Oncology 227
- Lung Cancer Research Studies 84
- Cancer Immunotherapy and Biomarkers 57
- Colorectal Cancer Treatments and Studies 44
- Co-authors
- Frances A. Shepherd (151 shared papers)Ronald Feld (53 shared papers)Ming‐Sound Tsao (86 shared papers)Monika K. Krzyzanowska (20 shared papers)Gary Rodin (11 shared papers)Camilla Zimmermann (9 shared papers)Nadia Swami (8 shared papers)Breffni Hannon (7 shared papers)
- Journals
- Journal of Clinical Oncology (150 papers)Journal of Thoracic Oncology (56 papers)Lung Cancer (39 papers)Clinical Lung Cancer (32 papers)Annals of Oncology (30 papers)
- Partner nations
- CanadaUnited StatesSpain
In The Last Decade
Natasha B. Leighl
519 papers receiving 18.8k citations
Natasha B. Leighl's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 7.3k
- Pulmonary and Respiratory Medicine 8.1k
- Cancer Research 2.3k
- Public Health, Environmental and Occupational Health 1.9k
- Geriatrics and Gerontology 165
Countries citing papers authored by Natasha B. Leighl
This map shows the geographic impact of Natasha B. Leighl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natasha B. Leighl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natasha B. Leighl more than expected).
Fields of papers citing papers by Natasha B. Leighl
This network shows the impact of papers produced by Natasha B. Leighl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natasha B. Leighl. The network helps show where Natasha B. Leighl may publish in the future.
Co-authors
The 25 scholars most cited alongside Natasha B. Leighl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 541 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial Hit paper breakdown → | 2014 | 1272 |
| 2 | Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL Hit paper breakdown → | 2009 | 1183 |
| 3 | Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2015 | 607 |
| 4 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 526 |
| 5 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Hit paper breakdown → | 2017 | 474 |
| 6 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Hit paper breakdown → | 2017 | 433 |
| 7 | Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Hit paper breakdown → | 2019 | 420 |
| 8 | 2005 | 408 | |
| 9 | 2004 | 405 | |
| 10 | Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update Hit paper breakdown → | 2018 | 348 |
| 11 | Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials Hit paper breakdown → | 2015 | 338 |
| 12 | 2005 | 279 | |
| 13 | Perceptions of palliative care among patients with advanced cancer and their caregivers Hit paper breakdown → | 2016 | 264 |
| 14 | 2007 | 246 | |
| 15 | 2014 | 217 | |
| 16 | 2016 | 202 | |
| 17 | 2017 | 191 | |
| 18 | 2009 | 187 | |
| 19 | 2009 | 186 | |
| 20 | 2015 | 182 |
About Natasha B. Leighl
Natasha B. Leighl is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Economics and Econometrics, having authored 541 papers that have together received 19.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (259 papers), Lung Cancer Research Studies (84 papers), Lung Cancer Diagnosis and Treatment (83 papers), Cancer Genomics and Diagnostics (71 papers), Cancer Immunotherapy and Biomarkers (57 papers), Colorectal Cancer Treatments and Studies (44 papers), Economic and Financial Impacts of Cancer (23 papers) and Gastric Cancer Management and Outcomes (20 papers). The work is most often cited by research in Oncology (7.3k citations), Pulmonary and Respiratory Medicine (8.1k citations), Cancer Research (2.3k citations), Public Health, Environmental and Occupational Health (1.9k citations) and Geriatrics and Gerontology (165 citations). Natasha B. Leighl has collaborated with scholars based in Canada, United States and Spain. Frequent co-authors include Frances A. Shepherd, Ronald Feld, Ming‐Sound Tsao, Monika K. Krzyzanowska, Gary Rodin, Camilla Zimmermann, Nadia Swami, Breffni Hannon, Ian F. Tannock and Anne Rydall. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.